Compared with conventional TLH, TLH without uterine manipulator can significantly reduce the levels of SCC-Ag, CEA, and CA125 in patients with early-stage cervical cancer within three years after surgery, without increasing postoperative complications or affecting survival, and has the same safety. The gene discussed is MUC16; the disease is cervical cancer.